Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

pembrolizumab 212Cyclophosphamide 120Nivolumab 110Carboplatin 92fludarabine 79Gemcitabine 79Specimen Handling 74Bevacizumab 73venetoclax 70Injections 70Magnetic Resonance Spectroscopy 68Paclitaxel 66Dexamethasone 66Biopsy 59atezolizumab 56Cisplatin 54Ipilimumab 49Temozolomide 45Lenalidomide 43Docetaxel 43Azacitidine 43Pemetrexed 42Rituximab 41Oxaliplatin 40Fluorouracil 40Radiotherapy 39Cetuximab 39durvalumab 37Cytarabine 36Capecitabine 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cell Count × 1 year × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡